



Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

No: 2017/SEC/NOV/160

November 20, 2017

National Stock Exchange of India Limited
"Exchange Plaza", 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex
Bandra (East), Mumbai – 400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

NSE - Symbol - BIOCON

BSE - Scrip code - 532523

Dear Sir,

Sub: Company Statement – "Biocon's Facility receives EIR with VAI status, Inspection Closed."

Please find below the Company's statement on the subject matter.

"Biocon confirms that the U.S. Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) in relation to the cGMP (current Good Manufacturing Practice) inspection of its aseptic drug product facility that was audited between 25th May – 3rd Jun 2017. The FDA has classified the outcome of this inspection as VAI ("voluntary action indicated") and the EIR states that the inspection is closed."

- *Company Spokesperson*

Kindly take on record the same.

Thanking You,

For **BIOCON LIMITED**


Rajiv Balakrishnan
Company Secretary